Default company panoramic image
59eae021 1125 49e3 9ac7 5a24e07f2443

Vivacelle Bio, Inc.

Vivacelle is developing an IV resuscitation fluid to treat hypovolemia. Est. $13 billion market and expedited regulatory pathway. Issued patents. Can relocate.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Chicago, IL, US
  • Currency USD
  • Founded August 2013
  • Employees 6
  • Incorporation Type C-corp
  • Website

Company Summary

Vivacelle Bio, has developed VBI-1, a phospholipid nanoparticle injectable to sustain life after severe injury causing hypovolemic shock. Competing products have toxicity and are more expensive. The formulation is based on non-toxic FDA-approved products that qualifies VBI-1 for an expedited FDA pathway. Preclinical studies show safety efficacy and protection from reperfusion injury. Experienced management. $13 billion addressable market.


  • E2495747 a7b8 4f76 b4bd 188b09f94b5c
    President and Chief Innovation Officer

    Dr. Simpkins is the inventor of Vivacelle. He is also a trauma surgeon and scientist with over thirty years of experience including serving as Director of the Trauma Program at LSU Health Sciences Center in Shreveport, LA. He achieved the rank of Commander and received two commendations for excellence in research while serving in the U.S. Navy which included several scientific discoveries and publications. MD- Harvard, BA-Amherst College

  • 0d2476cb 13c9 46f9 8341 a98b3b08cd29
    Chief Legal and Operating Officer

    Dr. DeShield is a pharmaceutical, biomedical and life sciences intellectual property attorney with more than eight years' experience. He is well-versed in Intellectual Property, patent litigation, patent prosecution, preparation, and trade secrets. His experience also encompasses food and drug law, regulatory law, anti-trust, contract, corporate and commercial law.
    Ph.D Biochemistry SUNY Buffalo School of Medicine, J.D. SUNY Buffalo Law School

  • 7f3f73ce 6f05 49ff ab44 66519a6d05cf
    Chief Medical Officer

    Dr.. Talluri is the owner of Compass Consulting International. She has over eighteen years of experience in drug development and medical affairs including stints at Johnson & Johnson, CATO, Lundbeck and Talecris Biotherapeutics. Her experience includes successful IND's and NDA's in CNS, neuroimmunology, immunology, pulmonary, oncology and other indications. Psychiatry Residency- Duke University Emergency Medicine-St. Lucia

  • Ec0f3ad9 1f05 4967 bba0 fd433d908ca2
    Chief Executive Officer

    25 years in biotech and pharma senior management, including President and COO at Panacea Pharma and Antex Biologics, VP North American Vaccine, and senior roles at Merck & Co. Success in raising capital for private and public companies. Experience in small molecules, vaccines, monoclonal antibodies, and cancer diagnostics, as well as marketing and sales, and business development


  • Default avatar
    Thomas Fitzgerald M.B.A.

Previous Investors

  • Default avatar
    Ron Damper